Sciele's sales network the main attraction for Shionogi
This article was originally published in Scrip
Executive Summary
Shionogi's $1.4 billion acquisition of the US firm Sciele Pharmaappears to be aimed squarely at securing access to a ready-made sales network in the US, where the Japanese company is planning to launch a number of new products over the next few years.